help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Endocrinology, doi:10.1210/en.2002-0185
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
144/7/3037    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Robitaille, R.
Right arrow Articles by Hallé, J.-P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Robitaille, R.
Right arrow Articles by Hallé, J.-P.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Islet Cell Transplantation
Endocrinology Vol. 144, No. 7 3037-3045
Copyright © 2003 by The Endocrine Society

Insulin-Like Growth Factor II Allows Prolonged Blood Glucose Normalization with a Reduced Islet Cell Mass Transplantation

Robert Robitaille, Julie Dusseault, Nathalie Henley, Lawrence Rosenberg and Jean-Pierre Hallé

Université de Montréal (R.R., J.D., N.H., J.-P.H.), Guy-Bernier Research Centre, Maisonneuve-Rosemont Hospital, Montréal, Québec, Canada H1T 2M4; and McGill University Health Center (L.R.), Montréal, Québec, Canada H3G 1A4

Address all correspondence and requests for reprints to: Jean-Pierre Hallé, M.D., Guy-Bernier Research Centre, Maisonneuve-Rosemont Hospital, 5415 boulevard de l’Assomption, Montréal, Québec, Canada H1T 2M4. E-mail: hallejp{at}videotron.ca.

IGF-II has been reported to decrease neonatal islet cell apoptosis and in vitro adult islet cell necrosis and apoptosis, but the usefulness of IGF-II in a transplantation setting is unknown. We evaluated the effect of in vitro IGF-II incubations on microencapsulated rat islet survival both in vitro and in minimal mass transplantations into diabetic mice. After 6 d in culture, fresh examinations, histology, fluorescence microscopy, sodium 3'-[1-(phenyl-amino-carbonyl)-3,4-tetrazolium]-bis (4-methoxy-6-nitro)-benzene sulfonic acid hydrate assay, and apoptosis studies all indicated that IGF-II significantly improves islet cell viability in a dose-dependent fashion. IGF-II 100 ng/ml and 500 ng/ml induced a 51% and 83% increase of viable islets (P = 0.052, P < 0.01). A 20%, 29%, and 33% reduction of the apoptotic index was observed with 50, 100, and 500 ng/ml incubations respectively (P < 0.05; P < 0.005; P < 0.001). Ten weeks after transplantation of 150 encapsulated rat islet equivalents incubated with IGF-II 500 ng/ml, 80% of diabetic mice were normoglycemic. Without IGF-II preincubation, only 8% of the recipients remained normoglycemic with the transplantation of 150 islets and 42% with 300 islets (P < 0.05). In conclusion, IGF-II promotes islet cell survival, and allows successful transplantation using a smaller number of islets.




This article has been cited by other articles:


Home page
DiabetesHome page
J. D. Rivas-Carrillo, A. Soto-Gutierrez, N. Navarro-Alvarez, H. Noguchi, T. Okitsu, Y. Chen, T. Yuasa, K. Tanaka, M. Narushima, A. Miki, et al.
Cell-Permeable Pentapeptide V5 Inhibits Apoptosis and Enhances Insulin Secretion, Allowing Experimental Single-Donor Islet Transplantation in Mice
Diabetes, May 1, 2007; 56(5): 1259 - 1267.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
Y. Lu, A. Ponton, H. Okamoto, S. Takasawa, P. L. Herrera, and J.-L. Liu
Activation of the Reg family genes by pancreatic-specific IGF-I gene deficiency and after streptozotocin-induced diabetes in mouse pancreas
Am J Physiol Endocrinol Metab, July 1, 2006; 291(1): E50 - E58.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
A. S. Narang and R. I. Mahato
Biological and biomaterial approaches for improved islet transplantation.
Pharmacol. Rev., June 1, 2006; 58(2): 194 - 243.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
Y. Lu, P. L. Herrera, Y. Guo, D. Sun, Z. Tang, D. LeRoith, and J.-L. Liu
Pancreatic-Specific Inactivation of IGF-I Gene Causes Enlarged Pancreatic Islets and Significant Resistance to Diabetes
Diabetes, December 1, 2004; 53(12): 3131 - 3141.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
N. Zhang, A. Richter, J. Suriawinata, S. Harbaran, J. Altomonte, L. Cong, H. Zhang, K. Song, M. Meseck, J. Bromberg, et al.
Elevated Vascular Endothelial Growth Factor Production in Islets Improves Islet Graft Vascularization
Diabetes, April 1, 2004; 53(4): 963 - 970.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2003 by The Endocrine Society